

Bibliography

- Ahamad, A., Stevens, C. W., Smythe, W. R., Vaporciyan, A. A., Komaki, R., Kelly, J. F., Liao, Z., Starkschall, G. and Forster, K. M. (2003).** "Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma." *Int J Radiat Oncol Biol Phys* **55**(3): 768-75.
- Ahn, W. S., Han, Y. J., Bae, S. M., Kim, T. H., Rho, M. S., Lee, J. M., Namkoong, S. E., Park, Y. S., Kim, C. K. and Sin, J. I. (2002).** "Differential suppression of human cervical cancer cell growth by adenovirus delivery of p53 in vitro: arrest phase of cell cycle is dependent on cell line." *Jpn J Cancer Res* **93**(9): 1012-9.
- Albelda, S. M., Wiewrodt, R. and Zuckerman, J. B. (2000).** "Gene therapy for lung disease: hype or hope?" *Ann Intern Med* **132**(8): 649-60.
- Aleman, R., Balague, C. and Curiel, D. T. (2000).** "Replicative adenoviruses for cancer therapy." *Nat Biotechnol* **18**(7): 723-7.
- Allen, A. M., Czerminska, M., Janne, P. A., Sugarbaker, D. J., Bueno, R., Harris, J. R., Court, L. and Baldini, E. H. (2006).** "Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma." *Int J Radiat Oncol Biol Phys* **65**(3): 640-5.
- Amalfitano, A., Hauser, M. A., Hu, H., Serra, D., Begy, C. R. and Chamberlain, J. S. (1998).** "Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted." *J Virol* **72**(2): 926-33.
- Anderson, B. D., Nakamura, T., Russell, S. J. and Peng, K. W. (2004).** "High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus." *Cancer Res* **64**(14): 4919-26.

- Aste-Amezaga, M., D'Andrea, A., Kubin, M. and Trinchieri, G. (1994).** "Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells." *Cell Immunol* **156**(2): 480-92.
- Astoul, P., Picat-Joossen, D., Viallat, J. R. and Boutin, C. (1998).** "Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study." *Cancer* **83**(10): 2099-104.
- Atabani, S. F., Byrnes, A. A., Jaye, A., Kidd, I. M., Magnusen, A. F., Whittle, H. and Karp, C. L. (2001).** "Natural measles causes prolonged suppression of interleukin-12 production." *J Infect Dis* **184**(1): 1-9.
- Ault, J. G., Cole, R. W., Jensen, C. G., Jensen, L. C., Bachert, L. A. and Rieder, C. L. (1995).** "Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells." *Cancer Res* **55**(4): 792-8.
- Aversa, G., Chang, C. C., Carballido, J. M., Cocks, B. G. and de Vries, J. E. (1997).** "Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production." *J Immunol* **158**(9): 4036-44.
- Aziz, T., Jilaihawi, A. and Prakash, D. (2002).** "The management of malignant pleural mesothelioma; single centre experience in 10 years." *Eur J Cardiothorac Surg* **22**(2): 298-305.
- Baker, A. H., Wilkinson, G. W., Hembry, R. M., Murphy, G. and Newby, A. C. (1996).** "Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit

smooth muscle cells and human MCF-7 adenocarcinoma cells." *Matrix Biol* **15**(6): 383-95.

Baldini, E. H. (2004). "External beam radiation therapy for the treatment of pleural mesothelioma." *Thorac Surg Clin* **14**(4): 543-8.

Balmain, A., Gray, J. and Ponder, B. (2003). "The genetics and genomics of cancer." *Nat Genet* **33 Suppl**: 238-44.

Balsara, B. R., Bell, D. W., Sonoda, G., De Rienzo, A., du Manoir, S., Jhanwar, S. C. and Testa, J. R. (1999). "Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma." *Cancer Res* **59**(2): 450-4.

Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J. P., van Kooten, C., Liu, Y. J., Rousset, F. and Saeland, S. (1994). "The CD40 antigen and its ligand." *Annu Rev Immunol* **12**: 881-922.

Barajas, M., Mazzolini, G., Genove, G., Bilbao, R., Narvaiza, I., Schmitz, V., Sangro, B., Melero, I., Qian, C. and Prieto, J. (2001). "Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12." *Hepatology* **33**(1): 52-61.

Battini, J. L., Danos, O. and Heard, J. M. (1995). "Receptor-binding domain of murine leukemia virus envelope glycoproteins." *J Virol* **69**(2): 713-9.

Bauerschmitz, G. J., Kanerva, A., Wang, M., Herrmann, I., Shaw, D. R., Strong, T. V., Desmond, R., Rein, D. T., Dall, P., Curiel, D. T. and Hemminki, A. (2004). "Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer." *Int J Cancer* **111**(2): 303-9.

- Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R. (1998).** "Help for cytotoxic-T-cell responses is mediated by CD40 signalling." *Nature* **393**(6684): 478-80.
- Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L. and Finberg, R. W. (1997).** "Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5." *Science* **275**(5304): 1320-3.
- Bernt, K. M., Ni, S., Tieu, A. T. and Lieber, A. (2005).** "Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy." *Cancer Res* **65**(10): 4343-52.
- Berry, G. (1991).** "Prediction of mesothelioma, lung cancer, and asbestosis in former Wittenoom asbestos workers." *Br J Ind Med* **48**(12): 793-802.
- Berry, G., de Klerk, N. H., Reid, A., Ambrosini, G. L., Fritschi, L., Olsen, N. J., Merler, E. and Musk, A. W. (2004).** "Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia." *Occup Environ Med* **61**(4): e14.
- Bessis, N., GarciaCozar, F. J. and Boissier, M. C. (2004).** "Immune responses to gene therapy vectors: influence on vector function and effector mechanisms." *Gene Ther* **11 Suppl 1**: S10-7.
- Bhagwat, S. V., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R. and Shapiro, L. H. (2001).** "CD13/APN is activated by angiogenic signals and is essential for capillary tube formation." *Blood* **97**(3): 652-9.
- Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A. and McCormick, F. (1996).**

"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells." *Science* **274**(5286): 373-6.

Bjorkqvist, A. M., Tammilehto, L., Anttila, S., Mattson, K. and Knuutila, S. (1997).

"Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma." *Br J Cancer* **75**(4): 523-7.

Borok, Z., Harboe-Schmidt, J. E., Brody, S. L., You, Y., Zhou, B., Li, X., Cannon,

P. M., Kim, K. J., Crandall, E. D. and Kasahara, N. (2001). "Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells." *J Virol* **75**(23): 11747-54.

Both, G. W. (2004). "Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector." *Immunol Cell Biol* **82**(2): 189-95.

Bottomley, A., Gaafar, R., Manegold, C., Burgers, S., Coens, C., Legrand, C.,

Vincent, M., Giaccone, G. and Van Meerbeeck, J. (2006). "Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study." *J Clin Oncol* **24**(9): 1435-42.

Boutin, C. and Rey, F. (1993). "Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis." *Cancer* **72**(2): 389-93.

Boutin, C., Nussbaum, E., Monnet, I., Bignon, J., Vanderschueren, R., Guerin, J.

C., Menard, O., Mignot, P., Dabouis, G. and Douillard, J. Y. (1994).

"Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma." *Cancer* **74**(9): 2460-7.

Broaddus, V. C., Dansen, T. B., Abayasiriwardana, K. S., Wilson, S. M., Finch, A. J., Swigart, L. B., Hunt, A. E. and Evan, G. I. (2005). "Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage." *J Biol Chem* **280**(13): 12486-93.

Brockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W. and Engleman, E. G. (1999). "Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration." *Clin Immunol* **92**(1): 67-75.

Brunetti-Pierri, N., Palmer, D. J., Beaudet, A. L., Carey, K. D., Finegold, M. and Ng, P. (2004). "Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates." *Hum Gene Ther* **15**(1): 35-46.

Bryce, J., Boschi-Pinto, C., Shibuya, K. and Black, R. E. (2005). "WHO estimates of the causes of death in children." *Lancet* **365**(9465): 1147-52.

Buchheit, A. D., Kumar, S., Grote, D. M., Lin, Y., von Messling, V., Cattaneo, R. B. and Fielding, A. K. (2003). "An oncolytic measles virus engineered to enter cells through the CD20 antigen." *Mol Ther* **7**(1): 62-72.

Byrne, M. J., Davidson, J. A., Musk, A. W., Dewar, J., van Hazel, G., Buck, M., de Klerk, N. H. and Robinson, B. W. (1999). "Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study." *J Clin Oncol* **17**(1): 25-30.

- Caminschi, I., Venetsanakos, E., Leong, C. C., Garlepp, M. J., Scott, B. and Robinson, B. W. (1998).** "Interleukin-12 induces an effective antitumor response in malignant mesothelioma." *Am J Respir Cell Mol Biol* **19**(5): 738-46.
- Caminschi, I., Venetsanakos, E., Leong, C. C., Garlepp, M. J., Robinson, B. W. and Scott, B. (1999).** "Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12." *Am J Respir Cell Mol Biol* **21**(3): 347-56.
- Carbone, M., Pass, H. I., Rizzo, P., Marinetti, M., Di Muzio, M., Mew, D. J., Levine, A. S. and Procopio, A. (1994).** "Simian virus 40-like DNA sequences in human pleural mesothelioma." *Oncogene* **9**(6): 1781-90.
- Carbone, M., Kratzke, R. A. and Testa, J. R. (2002).** "The pathogenesis of mesothelioma." *Semin Oncol* **29**(1): 2-17.
- Carmeliet, P., Mackman, N., Moons, L., Luther, T., Gressens, P., Van Vlaenderen, I., Demunck, H., Kasper, M., Breier, G., Evrard, P., Muller, M., Risau, W., Edgington, T. and Collen, D. (1996).** "Role of tissue factor in embryonic blood vessel development." *Nature* **383**(6595): 73-5.
- Castagneto, B., Zai, S., Mutti, L., Lazzaro, A., Ridolfi, R., Piccolini, E., Ardizzoni, A., Fumagalli, L., Valsuani, G. and Botta, M. (2001).** "Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients." *Lung Cancer* **31**(2-3): 303-10.
- Cathomen, T., Mrkic, B., Spehner, D., Drillien, R., Naef, R., Pavlovic, J., Aguzzi, A., Billeter, M. A. and Cattaneo, R. (1998).** "A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain." *Embo J* **17**(14): 3899-908.

- Cattaneo, R. (2004).** "Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet." *J Virol* **78**(9): 4385-8.
- Ceresoli, G. L., Chiti, A., Zucali, P. A., Cappuzzo, F., De Vincenzo, F., Cavina, R., Rodari, M., Poretti, D., Lutman, F. R. and Santoro, A. (2007).** "Assessment of tumor response in malignant pleural mesothelioma." *Cancer Treat Rev* **33**(6): 533-41.
- Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C. and Trinchieri, G. (1991).** "Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers." *J Exp Med* **173**(4): 869-79.
- Chirmule, N., Propert, K., Magosin, S., Qian, Y., Qian, R. and Wilson, J. (1999).** "Immune responses to adenovirus and adeno-associated virus in humans." *Gene Ther* **6**(9): 1574-83.
- Christmas, T. I., Manning, L. S., Davis, M. R., Robinson, B. W. and Garlepp, M. J. (1991).** "HLA antigen expression and malignant mesothelioma." *Am J Respir Cell Mol Biol* **5**(3): 213-20.
- Cichon, G., Boeckh-Herwig, S., Schmidt, H. H., Wehnes, E., Muller, T., Pring-Akerblom, P. and Burger, R. (2001).** "Complement activation by recombinant adenoviruses." *Gene Ther* **8**(23): 1794-800.
- Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., Roth, J. A., Hong, W. K., Brusio, P. and Goepfert, H. (1998).** "Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma." *J Clin Oncol* **16**(6): 2221-32.

- Cocks, B. G., Chang, C. C., Carballido, J. M., Yssel, H., de Vries, J. E. and Aversa, G. (1995).** "A novel receptor involved in T-cell activation." *Nature* **376**(6537): 260-3.
- Cripe, T. P., Dunphy, E. J., Holub, A. D., Saini, A., Vasi, N. H., Mahller, Y. Y., Collins, M. H., Snyder, J. D., Krasnykh, V., Curiel, D. T., Wickham, T. J., DeGregori, J., Bergelson, J. M. and Currier, M. A. (2001).** "Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells." *Cancer Res* **61**(7): 2953-60.
- Cross, D. and Burmester, J. K. (2006).** "Gene therapy for cancer treatment: past, present and future." *Clin Med Res* **4**(3): 218-27.
- Croyle, M. A., Yu, Q. C. and Wilson, J. M. (2000).** "Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions." *Hum Gene Ther* **11**(12): 1713-22.
- Csatary, L. K., Gosztonyi, G., Szeberenyi, J., Fabian, Z., Liszka, V., Bodey, B. and Csatary, C. M. (2004).** "MTH-68/H oncolytic viral treatment in human high-grade gliomas." *J Neurooncol* **67**(1-2): 83-93.
- Cugell, D. W. and Kamp, D. W. (2004).** "Asbestos and the pleura: a review." *Chest* **125**(3): 1103-17.
- Cunningham, C. and Davison, A. J. (1993).** "A cosmid-based system for constructing mutants of herpes simplex virus type 1." *Virology* **197**(1): 116-24.
- D'Andrea, A., Rengaraju, M., Valiante, N. M., Chehimi, J., Kubin, M., Aste, M., Chan, S. H., Kobayashi, M., Young, D., Nickbarg, E. and et al. (1992).** "Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells." *J Exp Med* **176**(5): 1387-98.

- Davidson, J. A., Musk, A. W., Wood, B. R., Morey, S., Ilton, M., Yu, L. L., Drury, P., Shilkin, K. and Robinson, B. W. (1998).** "Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma." *J Immunother* **21**(5): 389-98.
- Davis, J. J. and Fang, B. (2005).** "Oncolytic virotherapy for cancer treatment: challenges and solutions." *J Gene Med* **7**(11): 1380-9.
- Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. and Robinson, B. W. (1992).** "Establishment of a murine model of malignant mesothelioma." *Int J Cancer* **52**(6): 881-6.
- Dazzi, H., Hasleton, P. S., Thatcher, N., Wilkes, S., Swindell, R. and Chatterjee, A. K. (1990).** "Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody." *Br J Cancer* **61**(6): 924-6.
- De Klerk, N. H., Armstrong, B. K., Musk, A. W. and Hobbs, M. S. (1989).** "Predictions of future cases of asbestos-related disease among former miners and millers of crocidolite in Western Australia." *Med J Aust* **151**(11-12): 616-20.
- De Klerk, N. H., Musk, A. W., Williams, V., Filion, P. R., Whitaker, D. and Shilkin, K. B. (1996).** "Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia." *Am J Ind Med* **30**(5): 579-87.
- De Klerk, N. H. and Musk, A. W. (2002).** *Epidemiology of Mesothelioma. Mesothelioma. Robinson, Bws and Chahinian, Ap. London, Martin Dunitz: 339-50.*

- Dehecchi, M. C., Melotti, P., Bonizzato, A., Santacatterina, M., Chilosi, M. and Cabrini, G. (2001).** "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5." *J Virol* **75**(18): 8772-80.
- Demant, P. (2003).** "Cancer susceptibility in the mouse: genetics, biology and implications for human cancer." *Nat Rev Genet* **4**(9): 721-34.
- Denekamp, J., Dasu, A. and Waites, A. (1998).** "Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?" *Adv Enzyme Regul* **38**: 281-99.
- DeWeese, T. L., van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G. and Simons, J. W. (2001).** "A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy." *Cancer Res* **61**(20): 7464-72.
- Dhiman, N., Jacobson, R. M. and Poland, G. A. (2004).** "Measles virus receptors: SLAM and CD46." *Rev Med Virol* **14**(4): 217-29.
- Dingli, D., Peng, K. W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C. and Russell, S. J. (2004).** "Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter." *Blood* **103**(5): 1641-6.
- Dmitriev, I., Krasnykh, V., Miller, C. R., Wang, M., Kashentseva, E., Mikheeva, G., Belousova, N. and Curiel, D. T. (1998).** "An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a

coxsackievirus and adenovirus receptor-independent cell entry mechanism." *J Virol* **72**(12): 9706-13.

Dmitriev, I. P., Kashentseva, E. A. and Curiel, D. T. (2002). "Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX." *J Virol* **76**(14): 6893-9.

Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V. and Wold, W. S. (2001). "Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy." *J Virol* **75**(7): 3314-24.

Douglas, J. T., Miller, C. R., Kim, M., Dmitriev, I., Mikheeva, G., Krasnykh, V. and Curiel, D. T. (1999). "A system for the propagation of adenoviral vectors with genetically modified receptor specificities." *Nat Biotechnol* **17**(5): 470-5.

Edwards, J. G., McLaren, J., Jones, J. L., Waller, D. A. and O'Byrne, K. J. (2003). "Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura." *Br J Cancer* **88**(10): 1553-9.

Enders, J. F. and Peebles, T. C. (1954). "Propagation in tissue cultures of cytopathogenic agents from patients with measles." *Proc Soc Exp Biol Med* **86**(2): 277-86.

Enders, J. F., Bell, J. A., Dingle, J. H., Francis, T., Jr., Hilleman, M. R., Huebner, R. J. and Payne, A. M. (1956). "Adenoviruses: group name proposed for new respiratory-tract viruses." *Science* **124**(3212): 119-20.

Esolen, L. M., Ward, B. J., Moench, T. R. and Griffin, D. E. (1993). "Infection of monocytes during measles." *J Infect Dis* **168**(1): 47-52.

Esolen, L. M., Park, S. W., Hardwick, J. M. and Griffin, D. E. (1995). "Apoptosis as a cause of death in measles virus-infected cells." *J Virol* **69**(6): 3955-8.

- Evans, A. L. and Gleeson, F. V. (2004).** "Radiology in pleural disease: state of the art." *Respirology* **9**(3): 300-12.
- Fallaux, F. J., Bout, A., van der Velde, I., van den Wollenberg, D. J., Hehir, K. M., Keegan, J., Auger, C., Cramer, S. J., van Ormondt, H., van der Eb, A. J., Valerio, D. and Hoeben, R. C. (1998).** "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses." *Hum Gene Ther* **9**(13): 1909-17.
- Fanning, E. and Knippers, R. (1992).** "Structure and function of simian virus 40 large tumor antigen." *Annu Rev Biochem* **61**: 55-85.
- Fielding, A. K. (2005).** "Measles as a potential oncolytic virus." *Rev Med Virol* **15**(2): 135-42.
- Fields, B., Knipe, D. M. and Howley, P. M., et al (1996).** *Virology*. Philadelphia, Lippincott-Raven Publishers.
- Figova, K., Hrabeta, J. and Eckschlager, T. (2006).** "Reovirus - possible therapy of cancer." *Neoplasma* **53**(6): 457-62.
- Fitzpatrick, D. R., Bielefeldt-Ohmann, H., Himbeck, R. P., Jarnicki, A. G., Marzo, A. L. and Robinson, B. W. (1994).** "Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma." *Growth Factors* **11**(1): 29-44.
- Freeman, A. I., Zakay-Rones, Z., Gombori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., Galun, E. and Siegal, T. (2006).** "Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme." *Mol Ther* **13**(1): 221-8.

- Freytag, S. O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E. and Kim, J. H. (2002).** "Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer." *Cancer Res* **62**(17): 4968-76.
- Freytag, S. O., Stricker, H., Pegg, J., Paielli, D., Pradhan, D. G., Peabody, J., DePeralta-Venturina, M., Xia, X., Brown, S., Lu, M. and Kim, J. H. (2003).** "Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer." *Cancer Res* **63**(21): 7497-506.
- Fu, X., Parks, W. C. and Heinecke, J. W. (2007).** "Activation and silencing of matrix metalloproteinases." *Semin Cell Dev Biol* doi:10.1016/j.semcdb.2007.06.005.
- Fu, X., Parks, W. C. and Heinecke, J. W. (2008).** "Activation and silencing of matrix metalloproteinases." *Semin Cell Dev Biol* **19**(1): 2-13.
- Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K. and Kyritsis, A. P. (2000).** "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo." *Oncogene* **19**(1): 2-12.
- Gamble, J. R., Matthias, L. J., Meyer, G., Kaur, P., Russ, G., Faull, R., Berndt, M. C. and Vadas, M. A. (1993).** "Regulation of in vitro capillary tube formation by anti-integrin antibodies." *J Cell Biol* **121**(4): 931-43.
- Ganjavi, H., Gee, M., Narendran, A., Freedman, M. H. and Malkin, D. (2005).** "Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell

lines: sensitization to cisplatin and doxorubicin." *Cancer Gene Ther* **12**(4): 397-406.

Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z. and Wilson, J. M. (2003). "Adeno-associated viruses undergo substantial evolution in primates during natural infections." *Proc Natl Acad Sci U S A* **100**(10): 6081-6.

Gao, G. P., Yang, Y. and Wilson, J. M. (1996). "Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy." *J Virol* **70**(12): 8934-43.

Gao, X. and Huang, L. (1995). "Cationic liposome-mediated gene transfer." *Gene Ther* **2**(10): 710-22.

Gardlik, R., Palfy, R., Hodosy, J., Lukacs, J., Turna, J. and Celec, P. (2005). "Vectors and delivery systems in gene therapy." *Med Sci Monit* **11**(4): RA110-21.

Gately, M. K., Wolitzky, A. G., Quinn, P. M. and Chizzonite, R. (1992). "Regulation of human cytolytic lymphocyte responses by interleukin-12." *Cell Immunol* **143**(1): 127-42.

Gazdar, A. F. and Carbone, M. (2003). "Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40." *Clin Lung Cancer* **5**(3): 177-81.

Geraghty, R. J., Krummenacher, C., Cohen, G. H., Eisenberg, R. J. and Spear, P. G. (1998). "Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor." *Science* **280**(5369): 1618-20.

Goerres, G. W., von Schulthess, G. K. and Steinert, H. C. (2004). "Why most PET of lung and head-and-neck cancer will be PET/CT." *J Nucl Med* **45 Suppl 1**: 66S-71S.

- Goey, S. H., Eggermont, A. M., Punt, C. J., Slingerland, R., Gratama, J. W., Oosterom, R., Oskam, R., Bolhuis, R. L. and Stoter, G. (1995).** "Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study." *Br J Cancer* **72**(5): 1283-8.
- Goldman, M. J., Lee, P. S., Yang, J. S. and Wilson, J. M. (1997).** "Lentiviral vectors for gene therapy of cystic fibrosis." *Hum Gene Ther* **8**(18): 2261-8.
- Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D. and Lander, E. S. (1999).** "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring." *Science* **286**(5439): 531-7.
- Gomez-Navarro, J. and Curiel, D. T. (2000).** "Conditionally replicative adenoviral vectors for cancer gene therapy." *Lancet Oncol* **1**: 148-58.
- Gordon, G. J., Jensen, R. V., Hsiao, L. L., Gullans, S. R., Blumenstock, J. E., Ramaswamy, S., Richards, W. G., Sugarbaker, D. J. and Bueno, R. (2002).** "Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma." *Cancer Res* **62**(17): 4963-7.
- Gordon, G. J., Jensen, R. V., Hsiao, L. L., Gullans, S. R., Blumenstock, J. E., Richards, W. G., Jaklitsch, M. T., Sugarbaker, D. J. and Bueno, R. (2003).** "Using gene expression ratios to predict outcome among patients with mesothelioma." *J Natl Cancer Inst* **95**(8): 598-605.
- Gordon, G. J., Rockwell, G. N., Jensen, R. V., Rheinwald, J. G., Glickman, J. N., Aronson, J. P., Pottorf, B. J., Nitz, M. D., Richards, W. G., Sugarbaker, D. J. and Bueno, R. (2005).** "Identification of novel candidate oncogenes and

tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling." *Am J Pathol* **166**(6): 1827-40.

Graham, F. L., Smiley, J., Russell, W. C. and Nairn, R. (1977). "Characteristics of a human cell line transformed by DNA from human adenovirus type 5." *J Gen Virol* **36**(1): 59-74.

Griffin, D. E. (2001). Measles Virus. *Fields Virology*. Knipe, Dm, Howley, Pm, Griffin, De, Lamb, Ra, Martin, Ma, Roizman, B and Straus, Se. Philadelphia, Lippincot Williams & Wilkins. **4th edn:** 1401-41.

Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H. and Wimmer, E. (2000). "Intergeneric poliovirus recombinants for the treatment of malignant glioma." *Proc Natl Acad Sci U S A* **97**(12): 6803-8.

Grondin, S. C. and Sugarbaker, D. J. (1999). "Pleuropneumonectomy in the treatment of malignant pleural mesothelioma." *Chest* **116**(6 Suppl): 450S-4S.

Grote, D., Russell, S. J., Cornu, T. I., Cattaneo, R., Vile, R., Poland, G. A. and Fielding, A. K. (2001). "Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice." *Blood* **97**(12): 3746-54.

Grote, D., Cattaneo, R. and Fielding, A. K. (2003). "Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression." *Cancer Res* **63**(19): 6463-8.

Guerder, S. and Matzinger, P. (1992). "A fail-safe mechanism for maintaining self-tolerance." *J Exp Med* **176**(2): 553-64.

Hall, W. C., Kovatch, R. M., Herman, P. H. and Fox, J. G. (1971). "Pathology of measles in rhesus monkeys." *Vet Pathol* **8**(4): 307-19.

Hallak, L. K., Merchan, J. R., Storgard, C. M., Loftus, J. C. and Russell, S. J. (2005). "Targeted measles virus vector displaying echistatin infects endothelial

cells via alpha(v)beta3 and leads to tumor regression." *Cancer Res* **65**(12): 5292-300.

Hallenbeck, P. L., Chang, Y. N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S. and Chiang, Y. L. (1999). "A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma." *Hum Gene Ther* **10**(10): 1721-33.

Hammond, A. L., Plemper, R. K., Zhang, J., Schneider, U., Russell, S. J. and Cattaneo, R. (2001). "Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen." *J Virol* **75**(5): 2087-96.

Hanahan, D. and Gluzman, Y. (1984). "Rescue of functional replication origins from embedded configurations in a plasmid carrying the adenovirus genome." *Mol Cell Biol* **4**(2): 302-9.

Hanahan, D. and Weinberg, R. A. (2000). "The hallmarks of cancer." *Cell* **100**(1): 57-70.

Harada, J. N. and Berk, A. J. (1999). "p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication." *J Virol* **73**(7): 5333-44.

Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y. and Phipps, M. L. (1997). "Construction of adenovirus vectors through Cre-lox recombination." *J Virol* **71**(3): 1842-9.

Hasegawa, K., Pham, L., O'Connor, M. K., Federspiel, M. J., Russell, S. J. and Peng, K. W. (2006). "Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter." *Clin Cancer Res* **12**(6): 1868-75.

- Hashimoto, K., Ono, N., Tatsuo, H., Minagawa, H., Takeda, M., Takeuchi, K. and Yanagi, Y. (2002).** "SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein." *J Virol* **76**(13): 6743-9.
- Hassan, R., Bera, T. and Pastan, I. (2004).** "Mesothelin: a new target for immunotherapy." *Clin Cancer Res* **10**(12 Pt 1): 3937-42.
- Haviv, Y. S., Takayama, K., Glasgow, J. N., Blackwell, J. L., Wang, M., Lei, X. and Curiel, D. T. (2002).** "A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene." *Mol Cancer Ther* **1**(5): 321-8.
- Hay, J. G., Shapiro, N., Sauthoff, H., Heitner, S., Phupakdi, W. and Rom, W. N. (1999).** "Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene." *Hum Gene Ther* **10**(4): 579-90.
- Hedley, S. J., Chen, J., Mountz, J. D., Li, J., Curiel, D. T., Korokhov, N. and Kovesdi, I. (2006).** "Targeted and shielded adenovectors for cancer therapy." *Cancer Immunol Immunother* **55**(11): 1412-9.
- Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L. and Kirn, D. (2000).** "An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy." *Nat Med* **6**(10): 1134-9.
- Hemmi, S., Geertsens, R., Mezzacasa, A., Peter, I. and Dummer, R. (1998).** "The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures." *Hum Gene Ther* **9**(16): 2363-73.

- Henderson, R. A., Mossman, S., Nairn, N. and Cheever, M. A. (2005).** "Cancer vaccines and immunotherapies: emerging perspectives." *Vaccine* **23**(17-18): 2359-62.
- Hensley, S. E., Giles-Davis, W., McCoy, K. C., Weninger, W. and Ertl, H. C. (2005).** "Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors." *J Immunol* **175**(9): 6032-41.
- Hensley, S. E. and Amalfitano, A. (2007).** "Toll-like receptors impact on safety and efficacy of gene transfer vectors." *Mol Ther* **15**(8): 1417-22.
- Hermiston, T. W. and Kuhn, I. (2002).** "Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes." *Cancer Gene Ther* **9**(12): 1022-35.
- Hernandez-Alcoceba, R., Pihalja, M., Qian, D. and Clarke, M. F. (2002).** "New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication." *Hum Gene Ther* **13**(14): 1737-50.
- Heufler, C., Koch, F., Stanzl, U., Topar, G., Wysocka, M., Trinchieri, G., Enk, A., Steinman, R. M., Romani, N. and Schuler, G. (1996).** "Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells." *Eur J Immunol* **26**(3): 659-68.
- Hidalgo, M. and Eckhardt, S. G. (2001).** "Development of matrix metalloproteinase inhibitors in cancer therapy." *J Natl Cancer Inst* **93**(3): 178-93.
- Hodge, G., Hodge, S. and Han, P. (2000).** "Increased levels of apoptosis of leukocyte subsets in cultured PBMCs compared to whole blood as shown by Annexin V binding: relevance to cytokine production." *Cytokine* **12**(12): 1763-8.

- Hojilla, C. V., Mohammed, F. F. and Khokha, R. (2003).** "Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development." *Br J Cancer* **89**(10): 1817-21.
- Hong, S. S., Karayan, L., Tournier, J., Curiel, D. T. and Boulanger, P. A. (1997).** "Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells." *Embo J* **16**(9): 2294-306.
- Horikami, S. M. and Moyer, S. A. (1995).** "Structure, transcription, and replication of measles virus." *Curr Top Microbiol Immunol* **191**: 35-50.
- Huang, T. G., Savontaus, M. J., Shinozaki, K., Sauter, B. V. and Woo, S. L. (2003).** "Telomerase-dependent oncolytic adenovirus for cancer treatment." *Gene Ther* **10**(15): 1241-7.
- Hughes, R. M. (2004).** "Strategies for cancer gene therapy." *J Surg Oncol* **85**(1): 28-35.
- Huncharek, M., Kelsey, K., Muscat, J. and Christiani, D. (1996).** "Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study." *Cancer Lett* **102**(1-2): 205-8.
- Ijzermans, J. N. and Marquet, R. L. (1989).** "Interferon-gamma: a review." *Immunobiology* **179**(4-5): 456-73.
- Indraccolo, S., Gola, E., Rosato, A., Minuzzo, S., Habeler, W., Tisato, V., Roni, V., Esposito, G., Morini, M., Albini, A., Noonan, D. M., Ferrantini, M., Amadori, A. and Chieco-Bianchi, L. (2002).** "Differential effects of angiostatin, endostatin and interferon-alpha(1) gene transfer on in vivo growth of human breast cancer cells." *Gene Ther* **9**(13): 867-78.
- Iozzo, R. V. (1998).** "Matrix proteoglycans: from molecular design to cellular function." *Annu Rev Biochem* **67**: 609-52.

- Isayeva, T., Ren, C. and Ponnazhagan, S. (2005).** "Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer." *Clin Cancer Res* **11**(3): 1342-7.
- Ismail-Khan, R., Robinson, L. A., Williams, C. C., Jr., Garrett, C. R., Bepler, G. and Simon, G. R. (2006).** "Malignant pleural mesothelioma: a comprehensive review." *Cancer Control* **13**(4): 255-63.
- Janeway, C. A. and Travers, P. (1997).** Host defense against infection. *Immunobiology: the immune system in health and disease*. Austin, P, Lawrence, E and Robertson, M. New York, Garland. **9**(1-9): 52.
- Janeway, C. A. and Travers, P. (1997).** The humoral immune response. *Immunobiology: the immune system in health and disease*. Austin, P, Lawrence, E and Robertson, M. New York, Garland. **8**(1-8): 54.
- Jang, S. Y., Liu, H. H., Wang, X., Vassiliev, O. N., Siebers, J. V., Dong, L. and Mohan, R. (2006).** "Dosimetric verification for intensity-modulated radiotherapy of thoracic cancers using experimental and Monte Carlo approaches." *Int J Radiat Oncol Biol Phys* **66**(3): 939-48.
- Janne, P. A. (2003).** "Chemotherapy for malignant pleural mesothelioma." *Clin Lung Cancer* **5**(2): 98-106.
- Jin, F., Xie, Z., Kuo, C. J., Chung, L. W. and Hsieh, C. L. (2005).** "Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy." *Cancer Gene Ther* **12**(3): 257-67.
- Joseph, J. M., Bouquet, C., Opolon, P., Morizet, J., Aubert, G., Rossler, J., Gross, N., Griscelli, F., Perricaudet, M. and Vassal, G. (2003).** "High level of

- stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts." *Cancer Gene Ther* **10**(11): 859-66.
- Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L. and Verma, I. (1998).** "Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy." *Proc Natl Acad Sci U S A* **95**(19): 11377-82.
- Kahari, V. M. and Saarialho-Kere, U. (1999).** "Matrix metalloproteinases and their inhibitors in tumour growth and invasion." *Ann Med* **31**(1): 34-45.
- Kamp, D. W., Israbian, V. A., Preusen, S. E., Zhang, C. X. and Weitzman, S. A. (1995).** "Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals." *Am J Physiol* **268**(3 Pt 1): L471-80.
- Kanerva, A., Mikheeva, G. V., Krasnykh, V., Coolidge, C. J., Lam, J. T., Mahasreshti, P. J., Barker, S. D., Straughn, M., Barnes, M. N., Alvarez, R. D., Hemminki, A. and Curiel, D. T. (2002).** "Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells." *Clin Cancer Res* **8**(1): 275-80.
- Kanerva, A. and Hemminki, A. (2004).** "Modified adenoviruses for cancer gene therapy." *Int J Cancer* **110**(4): 475-80.
- Karmann, K., Hughes, C. C., Schechner, J., Fanslow, W. C. and Pober, J. S. (1995).** "CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression." *Proc Natl Acad Sci U S A* **92**(10): 4342-6.
- Karp, C. L., Wysocka, M., Wahl, L. M., Ahearn, J. M., Cuomo, P. J., Sherry, B., Trinchieri, G. and Griffin, D. E. (1996).** "Mechanism of suppression of cell-mediated immunity by measles virus." *Science* **273**(5272): 228-31.

- Kerbel, R. S. (2006).** "Antiangiogenic therapy: a universal chemosensitization strategy for cancer?" *Science* **312**(5777): 1171-5.
- Kerdiles, Y. M., Sellin, C. I., Druelle, J. and Horvat, B. (2006).** "Immunosuppression caused by measles virus: role of viral proteins." *Rev Med Virol* **16**(1): 49-63.
- Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Brusio, P., Kaye, S. B., Hong, W. K. and Kirn, D. H. (2000).** "a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer." *Nat Med* **6**(8): 879-85.
- Kim, W. J., Yockman, J. W., Lee, M., Jeong, J. H., Kim, Y. H. and Kim, S. W. (2005).** "Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis." *J Control Release* **106**(1-2): 224-34.
- Kindler, H. L. (2000).** "Malignant pleural mesothelioma." *Curr Treat Options Oncol* **1**(4): 313-26.
- Kindler, H. L., Millard, F., Herndon, J. E., 2nd, Vogelzang, N. J., Suzuki, Y. and Green, M. R. (2001).** "Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B." *Lung Cancer* **31**(2-3): 311-7.
- Kindler, H. L. (2004).** "Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma." *Lung Cancer* **45 Suppl 1**: S125-7.
- Kindler, H. L., Karrison, T. and Lu, C., et al (2005).** "A multi-center, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma." *Proc Am Soc Clin Oncol* **23**(16s): 625s.

- Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B. and Trinchieri, G. (1989).** "Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes." *J Exp Med* **170**(3): 827-45.
- Kobune, F., Takahashi, H., Terao, K., Ohkawa, T., Ami, Y., Suzaki, Y., Nagata, N., Sakata, H., Yamanouchi, K. and Kai, C. (1996).** "Nonhuman primate models of measles." *Lab Anim Sci* **46**(3): 315-20.
- Koglin, J. and Russell, M. E. (1999).** "Alloimmune-mediated apoptosis: comparison in mouse models of acute and chronic cardiac rejection." *Transplantation* **67**(6): 904-9.
- Kohn, D. B., Sadelain, M., Dunbar, C., Bodine, D., Kiem, H. P., Candotti, F., Tisdale, J., Riviere, I., Blau, C. A., Richard, R. E., Sorrentino, B., Nolte, J., Malech, H., Brenner, M., Cornetta, K., Cavagnaro, J., High, K. and Glorioso, J. (2003).** "American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells." *Mol Ther* **8**(2): 180-7.
- Konig, J. E., Tolnay, E., Wiethege, T. and Muller, K. M. (1999).** "Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma." *Virchows Arch* **435**(1): 8-12.
- Kootstra, N. A. and Verma, I. M. (2003).** "Gene therapy with viral vectors." *Annu Rev Pharmacol Toxicol* **43**: 413-39.
- Krougliak, V. and Graham, F. L. (1995).** "Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants." *Hum Gene Ther* **6**(12): 1575-86.

- Krug, A., Luker, G. D., Barchet, W., Leib, D. A., Akira, S. and Colonna, M. (2004).** "Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9." *Blood* **103**(4): 1433-7.
- Kumar, C. C. (2003).** "Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis." *Curr Drug Targets* **4**(2): 123-31.
- Kumar-Singh, S., Vermeulen, P. B., Weyler, J., Segers, K., Weyn, B., Van Daele, A., Dirix, L. Y., Van Oosterom, A. T. and Van Marck, E. (1997).** "Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma." *J Pathol* **182**(2): 211-6.
- Kurihara, T., Brough, D. E., Kovesdi, I. and Kufe, D. W. (2000).** "Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen." *J Clin Invest* **106**(6): 763-71.
- Kurts, C., Kosaka, H., Carbone, F. R., Miller, J. F. and Heath, W. R. (1997).** "Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells." *J Exp Med* **186**(2): 239-45.
- Lam, J. T., Bauerschmitz, G. J., Kanerva, A., Barker, S. D., Straughn, J. M., Wang, M., Barnes, M. N., Blackwell, J. L., Siegal, G. P., Alvarez, R. D., Curiel, D. T. and Hemminki, A. (2003).** "Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids." *Cancer Gene Ther* **10**(5): 377-87.
- Lamfers, M. L., Grill, J., Dirven, C. M., Van Beusechem, V. W., Geogerger, B., Van Den Berg, J., Alemany, R., Fueyo, J., Curiel, D. T., Vassal, G., Pinedo, H. M., Vandertop, W. P. and Gerritsen, W. R. (2002).** "Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of

malignant gliomas and its enhanced effect with radiotherapy." *Cancer Res* **62**(20): 5736-42.

Lamont, J. P., Nemunaitis, J., Kuhn, J. A., Landers, S. A. and McCarty, T. M.

(2000). "A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)." *Ann Surg Oncol* **7**(8): 588-92.

Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S.,

Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., Chandler, W., Zwiebel, J. A., Kaplan, R. S. and Yung, W. K. (2003). "Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results." *J Clin Oncol* **21**(13): 2508-18.

Lanphear, B. P. and Buncher, C. R. (1992). "Latent period for malignant

mesothelioma of occupational origin." *J Occup Med* **34**(7): 718-21.

Laurent, T. C. and Fraser, J. R. (1992). "Hyaluronan." *Faseb J* **6**(7): 2397-404.

Lee, A. Y., He, B., You, L., Dadfarmay, S., Xu, Z., Mazieres, J., Mikami, I.,

McCormick, F. and Jablons, D. M. (2004). "Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma." *Oncogene* **23**(39): 6672-6.

Lee, Y. C., Light, R. W. and Musk, A. W. (2000). "Management of malignant pleural

mesothelioma: a critical review." *Curr Opin Pulm Med* **6**(4): 267-74.

Lee, Y. C., Thompson, R. I., Dean, A. and S, R. B. W. (2002). Clinical and palliative

care aspects of malignant mesothelioma. *Mesothelioma*. Robinson, Bws and Chahinian, Ap. London, Martin Dunitz: 111-26.

Leigh, J. and Davidson, P., et al (2002). "Malignant mesothelioma in Australia,1945-

2000." *Am J Ind Med* **41**: 188-201.

- Leigh, J. and Robinson, B. W. S. (2002).** The history of Mesothelioma in Australia 1945-2001. Mesothelioma. Robinson, Bws and Chahinian, Ap. London, Martin Dunitz: 55-110.
- Leong, C. C., Robinson, B. W. and Garlepp, M. J. (1994).** "Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes." *Int J Cancer* **59**(2): 212-6.
- Leong, C. C., Marley, J. V., Loh, S., Milech, N., Robinson, B. W. and Garlepp, M. J. (1997).** "Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma." *Int J Cancer* **71**(3): 476-82.
- Leong, C. C., Marley, J. V., Loh, S., Robinson, B. W. and Garlepp, M. J. (1997).** "The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer." *Immunol Cell Biol* **75**(4): 356-9.
- Leung, A. N., Muller, N. L. and Miller, R. R. (1990).** "CT in differential diagnosis of diffuse pleural disease." *AJR Am J Roentgenol* **154**(3): 487-92.
- Lewis, P., Hensel, M. and Emerman, M. (1992).** "Human immunodeficiency virus infection of cells arrested in the cell cycle." *Embo J* **11**(8): 3053-8.
- Li, Y., Pong, R. C., Bergelson, J. M., Hall, M. C., Sagalowsky, A. I., Tseng, C. P., Wang, Z. and Hsieh, J. T. (1999).** "Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy." *Cancer Res* **59**(2): 325-30.
- Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A. and Hemminki, K. (2000).** "Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland." *N Engl J Med* **343**(2): 78-85.

- Lieber, A., Steinwaerder, D. S., Carlson, C. A. and Kay, M. A. (1999).** "Integrating adenovirus-adenovirus-associated virus hybrid vectors devoid of all viral genes." *J Virol* **73**(11): 9314-24.
- Linder, C., Linder, S., Munck-Wikland, E. and Strander, H. (1998).** "Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma." *Anticancer Res* **18**(3B): 2063-8.
- Liszewski, M. K., Post, T. W. and Atkinson, J. P. (1991).** "Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster." *Annu Rev Immunol* **9**: 431-55.
- Liu, F., Yang, J., Huang, L. and Liu, D. (1996).** "New cationic lipid formulations for gene transfer." *Pharm Res* **13**(12): 1856-60.
- Liu, Q., Zaiss, A. K., Colarusso, P., Patel, K., Haljan, G., Wickham, T. J. and Muruve, D. A. (2003).** "The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors." *Hum Gene Ther* **14**(7): 627-43.
- Liu, Y. and Deisseroth, A. (2006).** "Tumor vascular targeting therapy with viral vectors." *Blood* **107**(8): 3027-33.
- Lopez-Rios, F., Illei, P. B., Rusch, V. and Ladanyi, M. (2004).** "Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids." *Lancet* **364**(9440): 1157-66.
- Lukashok, S. A. and Horwitz, M. S. (1998).** "New perspectives in adenoviruses." *Curr Clin Top Infect Dis* **18**: 286-305.

- Lund, J., Sato, A., Akira, S., Medzhitov, R. and Iwasaki, A. (2003).** "Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells." *J Exp Med* **198**(3): 513-20.
- Lundstrom, K. (2003).** "Latest development in viral vectors for gene therapy." *Trends Biotechnol* **21**(3): 117-22.
- Lusky, M., Christ, M., Rittner, K., Dieterle, A., Dreyer, D., Mourot, B., Schultz, H., Stoeckel, F., Pavirani, A. and Mehtali, M. (1998).** "In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted." *J Virol* **72**(3): 2022-32.
- Majhen, D. and Ambriovic-Ristov, A. (2006).** "Adenoviral vectors--how to use them in cancer gene therapy?" *Virus Res* **119**(2): 121-33.
- Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G. and Romagnani, S. (1993).** "Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells." *J Exp Med* **177**(4): 1199-204.
- Manfredi, J. J., Dong, J., Liu, W. J., Resnick-Silverman, L., Qiao, R., Chahinian, P., Saric, M., Gibbs, A. R., Phillips, J. I., Murray, J., Axten, C. W., Nolan, R. P. and Aaronson, S. A. (2005).** "Evidence against a role for SV40 in human mesothelioma." *Cancer Res* **65**(7): 2602-9.
- Manning, L. S., Bowman, R. V., Darby, S. B. and Robinson, B. W. (1989).** "Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells." *Am Rev Respir Dis* **139**(6): 1369-74.
- Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., Couto, L. B.,**

- Leonard, D. G., Johnson, F. A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A. W., Kay, M. A., High, K. A. and Glader, B. (2003).** "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B." *Blood* **101**(8): 2963-72.
- Marzo, A. L., Fitzpatrick, D. R., Robinson, B. W. and Scott, B. (1997).** "Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo." *Cancer Res* **57**(15): 3200-7.
- Masood, R., Kundra, A., Zhu, S., Xia, G., Scalia, P., Smith, D. L. and Gill, P. S. (2003).** "Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops." *Int J Cancer* **104**(5): 603-10.
- McChesney, M. B., Miller, C. J., Rota, P. A., Zhu, Y. D., Antipa, L., Lerche, N. W., Ahmed, R. and Bellini, W. J. (1997).** "Experimental measles. I. Pathogenesis in the normal and the immunized host." *Virology* **233**(1): 74-84.
- McDonald, A. D. and McDonald, J. C. (1987).** Epidemiology of malignant mesothelioma. Asbestos-related Malignancy. Antman, K and Aisner, J. Orlando, Grune and Stratton: 31-55.
- McDonald, D. M. and Foss, A. J. (2000).** "Endothelial cells of tumor vessels: abnormal but not absent." *Cancer Metastasis Rev* **19**(1-2): 109-20.
- Mei, Y. F., Segerman, A., Lindman, K., Hornsten, P., Wahlin, A. and Wadell, G. (2004).** "Human hematopoietic (CD34+) stem cells possess high-affinity receptors for adenovirus type 11p." *Virology* **328**(2): 198-207.
- Meier, O. and Greber, U. F. (2004).** "Adenovirus endocytosis." *J Gene Med* **6 Suppl 1**: S152-63.

- Meredith, J. E., Jr., Winitz, S., Lewis, J. M., Hess, S., Ren, X. D., Renshaw, M. W. and Schwartz, M. A. (1996).** "The regulation of growth and intracellular signaling by integrins." *Endocr Rev* **17**(3): 207-20.
- Merritt, R. E., Yamada, R. E., Wasif, N., Crystal, R. G. and Korst, R. J. (2004).** "Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma." *Ann Thorac Surg* **78**(3): 1042-51; discussion -51.
- Metcalf, D. (1989).** "Haemopoietic growth factors 1." *Lancet* **1**(8642): 825-7.
- Miller, C. R., Buchsbaum, D. J., Reynolds, P. N., Douglas, J. T., Gillespie, G. Y., Mayo, M. S., Raben, D. and Curiel, D. T. (1998).** "Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer." *Cancer Res* **58**(24): 5738-48.
- Miller, D. G., Adam, M. A. and Miller, A. D. (1990).** "Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection." *Mol Cell Biol* **10**(8): 4239-42.
- Modesitt, S. C., Ramirez, P., Zu, Z., Bodurka-Bervers, D., Gershenson, D. and Wolf, J. K. (2001).** "In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer." *Clin Cancer Res* **7**(6): 1765-72.
- Molinier-Frenkel, V., Gahery-Segard, H., Mehtali, M., Le Boulaire, C., Ribault, S., Boulanger, P., Tursz, T., Guillet, J. G. and Farace, F. (2000).** "Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes." *J Virol* **74**(16): 7678-82.
- Molnar-Kimber, K. L., Serman, D. H., Chang, M., Kang, E. H., ElBash, M., Lanuti, M., Elshami, A., Gelfand, K., Wilson, J. M., Kaiser, L. R. and**

- Albelda, S. M. (1998).** "Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma." *Hum Gene Ther* **9**(14): 2121-33.
- Moolten, F. L. (1986).** "Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy." *Cancer Res* **46**(10): 5276-81.
- Moolten, F. L. (1994).** "Drug sensitivity ("suicide") genes for selective cancer chemotherapy." *Cancer Gene Ther* **1**(4): 279-87.
- Moorhead, J. W., Clayton, G. H., Smith, R. L. and Schaack, J. (1999).** "A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears." *J Virol* **73**(2): 1046-53.
- Morrissey, P. J., Bressler, L., Park, L. S., Alpert, A. and Gillis, S. (1987).** "Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells." *J Immunol* **139**(4): 1113-9.
- Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., Hamblett, N. and Heald, A. E. (2004).** "Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial." *Chest* **125**(2): 509-21.
- Moss, W. J., Ryon, J. J., Monze, M. and Griffin, D. E. (2002).** "Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children." *J Infect Dis* **186**(7): 879-87.

- Moss, W. J., Ota, M. O. and Griffin, D. E. (2004).** "Measles: immune suppression and immune responses." *Int J Biochem Cell Biol* **36**(8): 1380-5.
- Mossman, B. T., Bignon, J., Corn, M., Seaton, A. and Gee, J. B. (1990).** "Asbestos: scientific developments and implications for public policy." *Science* **247**(4940): 294-301.
- Mossman, B. T. and Churg, A. (1998).** "Mechanisms in the pathogenesis of asbestosis and silicosis." *Am J Respir Crit Care Med* **157**(5 Pt 1): 1666-80.
- Mrkic, B., Pavlovic, J., Rulicke, T., Volpe, P., Buchholz, C. J., Hourcade, D., Atkinson, J. P., Aguzzi, A. and Cattaneo, R. (1998).** "Measles virus spread and pathogenesis in genetically modified mice." *J Virol* **72**(9): 7420-7.
- Mrkic, B., Odermatt, B., Klein, M. A., Billeter, M. A., Pavlovic, J. and Cattaneo, R. (2000).** "Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice." *J Virol* **74**(3): 1364-72.
- Mukherjee, S. and Robinson, B. W. S. (2002).** Immunotherapy of malignant mesothelioma. *Mesothelioma*. Robinson, Bws and Chahinian, Ap. London, Martin Dunitz: 325-38.
- Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C. and Kirn, D. (2001).** "Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial." *Gene Ther* **8**(4): 308-15.
- Murphy, G., Stanton, H., Cowell, S., Butler, G., Knauper, V., Atkinson, S. and Gavrilovic, J. (1999).** "Mechanisms for pro matrix metalloproteinase activation." *Apmis* **107**(1): 38-44.

- Murthy, S. S. and Testa, J. R. (1999).** "Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma." *J Cell Physiol* **180**(2): 150-7.
- Musti, M., Cavone, D., Aalto, Y., Scattone, A., Serio, G. and Knuutila, S. (2002).** "A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly." *Cancer Genet Cytogenet* **138**(1): 73-6.
- Mutsaers, S. E. (2004).** "The mesothelial cell." *Int J Biochem Cell Biol* **36**(1): 9-16.
- Nakamura, M., Iwahashi, M., Nakamori, M., Ueda, K., Matsuura, I., Noguchi, K. and Yamaue, H. (2002).** "Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity." *Clin Cancer Res* **8**(8): 2742-9.
- Nakamura, T. and Russell, S. J. (2004).** "Oncolytic measles viruses for cancer therapy." *Expert Opin Biol Ther* **4**(10): 1685-92.
- Naniche, D., Yeh, A., Eto, D., Manchester, M., Friedman, R. M. and Oldstone, M. B. (2000).** "Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production." *J Virol* **74**(16): 7478-84.
- Nemerow, G. R. and Stewart, P. L. (1999).** "Role of alpha(v) integrins in adenovirus cell entry and gene delivery." *Microbiol Mol Biol Rev* **63**(3): 725-34.
- Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S. and Kirn, D. (2001).** "Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity." *Gene Ther* **8**(10): 746-59.

- Nemunaitis, J. (2003).** "GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer." *J Control Release* **91**(1-2): 225-31.
- Neufeld, G., Cohen, T., Gengrinovitch, S. and Poltorak, Z. (1999).** "Vascular endothelial growth factor (VEGF) and its receptors." *Faseb J* **13**(1): 9-22.
- Nguyen, G. K., Akin, M. R., Villanueva, R. R. and Slatnik, J. (1999).** "Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy." *Diagn Cytopathol* **21**(4): 253-9.
- Nicholson, W. J. (1991).** "Comparative dose-response relationships of asbestos fiber types: magnitudes and uncertainties." *Ann N Y Acad Sci* **643**: 74-84.
- Nicklin, S. A., Dishart, K. L., Buening, H., Reynolds, P. N., Hallek, M., Nemerow, G. R., Von Seggern, D. J. and Baker, A. H. (2003).** "Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors." *Cancer Lett* **201**(2): 165-73.
- Nishizaki, M., Fujiwara, T., Tanida, T., Hizuta, A., Nishimori, H., Tokino, T., Nakamura, Y., Bouvet, M., Roth, J. A. and Tanaka, N. (1999).** "Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect." *Clin Cancer Res* **5**(5): 1015-23.
- Nishizaki, M., Meyn, R. E., Levy, L. B., Atkinson, E. N., White, R. A., Roth, J. A. and Ji, L. (2001).** "Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo." *Clin Cancer Res* **7**(9): 2887-97.
- Nociari, M., Ocheretina, O., Schoggins, J. W. and Falck-Pedersen, E. (2007).** "Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator." *J Virol* **81**(8): 4145-57.

- Noureddini, S. C. and Curiel, D. T. (2005).** "Genetic targeting strategies for adenovirus." *Mol Pharm* **2**(5): 341-7.
- Nowak, A. K., Byrne, M. J., Williamson, R., Ryan, G., Segal, A., Fielding, D., Mitchell, P., Musk, A. W. and Robinson, B. W. (2002).** "A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma." *Br J Cancer* **87**(5): 491-6.
- Nowak, A. K., Lake, R. A., Kindler, H. L. and Robinson, B. W. (2002).** "New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents." *Semin Oncol* **29**(1): 82-96.
- Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A. and Robinson, B. W. (2003).** "Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells." *J Immunol* **170**(10): 4905-13.
- Nowak, A. K., Robinson, B. W. and Lake, R. A. (2003).** "Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors." *Cancer Res* **63**(15): 4490-6.
- O'Brien, M. E., Watkins, D., Ryan, C., Priest, K., Corbishley, C., Norton, A., Ashley, S., Rowell, N. and Sayer, R. (2006).** "A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial." *Ann Oncol* **17**(2): 270-5.
- Odaka, M., Sterman, D. H., Wiewrodt, R., Zhang, Y., Kiefer, M., Amin, K. M., Gao, G. P., Wilson, J. M., Barsoum, J., Kaiser, L. R. and Albelda, S. M. (2001).** "Eradication of intraperitoneal and distant tumor by adenovirus-

mediated interferon-beta gene therapy is attributable to induction of systemic immunity." *Cancer Res* **61**(16): 6201-12.

Oehmig, A., Fraefel, C. and Breakefield, X. O. (2004). "Update on herpesvirus amplicon vectors." *Mol Ther* **10**(4): 630-43.

Ohbayashi, H. (2002). "Matrix metalloproteinases in lung diseases." *Curr Protein Pept Sci* **3**(4): 409-21.

Ohta, Y., Shridhar, V., Bright, R. K., Kalemkerian, G. P., Du, W., Carbone, M., Watanabe, Y. and Pass, H. I. (1999). "VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours." *Br J Cancer* **81**(1): 54-61.

Okada, Y., Okada, N., Mizuguchi, H., Hayakawa, T., Nakagawa, S. and Mayumi, T. (2005). "Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma." *Cancer Gene Ther* **12**(7): 608-16.

Okegawa, T., Li, Y., Pong, R. C., Bergelson, J. M., Zhou, J. and Hsieh, J. T. (2000). "The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy." *Cancer Res* **60**(18): 5031-6.

O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E. and Francis, G. E. (1999). "PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo." *Hum Gene Ther* **10**(8): 1349-58.

Osunkoya, B. O., Ukaejiofo, E. O., Ajayi, O. and Akinyemi, A. A. (1990). "Evidence that circulating lymphocytes act as vehicles or viraemia in measles." *West Afr J Med* **9**(1): 35-9.

- Pagliaro, L. C., Keyhani, A., Liu, B., Perrotte, P., Wilson, D. and Dinney, C. P. (2003).** "Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin." *Urol Oncol* **21**(6): 456-62.
- Palosaari, H., Parisien, J. P., Rodriguez, J. J., Ulane, C. M. and Horvath, C. M. (2003).** "STAT protein interference and suppression of cytokine signal transduction by measles virus V protein." *J Virol* **77**(13): 7635-44.
- Parker, L. P., Wolf, J. K. and Price, J. E. (2000).** "Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines." *Ann Clin Lab Sci* **30**(4): 395-405.
- Pass, H. I., Kranda, K., Temeck, B. K., Feuerstein, I. and Steinberg, S. M. (1997).** "Surgically debulked malignant pleural mesothelioma: results and prognostic factors." *Ann Surg Oncol* **4**(3): 215-22.
- Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., Carbone, M., Webb, C. and Wali, A. (2005).** "Asbestos exposure, pleural mesothelioma, and serum osteopontin levels." *N Engl J Med* **353**(15): 1564-73.
- Paulie, S., Ehlin-Henriksson, B., Mellstedt, H., Koho, H., Ben-Aissa, H. and Perlmann, P. (1985).** "A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes." *Cancer Immunol Immunother* **20**(1): 23-8.
- Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K. and Lorence, R. M. (2002).** "Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers." *J Clin Oncol* **20**(9): 2251-66.

- Peng, K. W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R. and Russell, S. J. (2001).** "Systemic therapy of myeloma xenografts by an attenuated measles virus." *Blood* **98**(7): 2002-7.
- Peng, K. W., TenEyck, C. J., Galanis, E., Kalli, K. R., Hartmann, L. C. and Russell, S. J. (2002).** "Intraperitoneal therapy of ovarian cancer using an engineered measles virus." *Cancer Res* **62**(16): 4656-62.
- Peng, K. W., Donovan, K. A., Schneider, U., Cattaneo, R., Lust, J. A. and Russell, S. J. (2003).** "Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker." *Blood* **101**(7): 2557-62.
- Peng, K. W., Frenzke, M., Myers, R., Soeffker, D., Harvey, M., Greiner, S., Galanis, E., Cattaneo, R., Federspiel, M. J. and Russell, S. J. (2003).** "Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice." *Hum Gene Ther* **14**(16): 1565-77.
- Peng, Z. (2005).** "Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers." *Hum Gene Ther* **16**(9): 1016-27.
- Persano, L., Crescenzi, M. and Indraccolo, S. (2007).** "Anti-angiogenic gene therapy of cancer: Current status and future prospects." *Mol Aspects Med* **28**(1): 87-114.
- Peto, J., Hodgson, J. T., Matthews, F. E. and Jones, J. R. (1995).** "Continuing increase in mesothelioma mortality in Britain." *Lancet* **345**(8949): 535-9.
- Peto, J. and Mack, T. M. (2000).** "High constant incidence in twins and other relatives of women with breast cancer." *Nat Genet* **26**(4): 411-4.
- Phan-Bich, L., Buard, A., Petit, J. F., Zeng, L., Tenu, J. P., Chretien, P., Monnet, I., Boutin, C., Bignon, J., Lemaire, G. and Jaurand, M. C. (1997).** "Differential responsiveness of human and rat mesothelioma cell lines to recombinant interferon-gamma." *Am J Respir Cell Mol Biol* **16**(2): 178-86.

- Phuong, L. K., Allen, C., Peng, K. W., Giannini, C., Greiner, S., TenEyck, C. J., Mishra, P. K., Macura, S. I., Russell, S. J. and Galanis, E. C. (2003).** "Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme." *Cancer Res* **63**(10): 2462-9.
- Pisters, L. L., Pettaway, C. A., Troncoso, P., McDonnell, T. J., Stephens, L. C., Wood, C. G., Do, K. A., Brisbay, S. M., Wang, X., Hossan, E. A., Evans, R. B., Soto, C., Jacobson, M. G., Parker, K., Merritt, J. A., Steiner, M. S. and Logothetis, C. J. (2004).** "Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer." *Clin Cancer Res* **10**(8): 2587-93.
- Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D., Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S. and Golub, T. R. (2002).** "Prediction of central nervous system embryonal tumour outcome based on gene expression." *Nature* **415**(6870): 436-42.
- Pott, F., Ziem, U., Reiffer, F. J., Huth, F., Ernst, H. and Mohr, U. (1987).** "Carcinogenicity studies on fibres, metal compounds, and some other dusts in rats." *Exp Pathol* **32**(3): 129-52.
- Purcell, W. T., Rudek, M. A. and Hidalgo, M. (2002).** "Development of matrix metalloproteinase inhibitors in cancer therapy." *Hematol Oncol Clin North Am* **16**(5): 1189-227.

- Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V. and Srivastava, A. (1999).** "Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2." *Nat Med* **5**(1): 71-7.
- Ra, H. J. and Parks, W. C. (2007).** "Control of matrix metalloproteinase catalytic activity." *Matrix Biol* **26**(8): 587-96.
- Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X. and Samulski, R. J. (2002).** "Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity." *J Virol* **76**(2): 791-801.
- Raetz, E. A. and Moos, P. J. (2004).** "Impact of microarray technology in clinical oncology." *Cancer Invest* **22**(2): 312-20.
- Raikwar, S. P., Temm, C. J., Raikwar, N. S., Kao, C., Molitoris, B. A. and Gardner, T. A. (2005).** "Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model." *Mol Ther* **12**(6): 1091-100.
- Ramos-Nino, M. E., Scapoli, L., Martinelli, M., Land, S. and Mossman, B. T. (2003).** "Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma." *Cancer Res* **63**(13): 3539-45.
- Rao, J. S., Gondi, C., Chetty, C., Chittivelu, S., Joseph, P. A. and Lakka, S. S. (2005).** "Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells." *Mol Cancer Ther* **4**(9): 1399-408.
- Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J. and Kirn, D. (2001).** "Intra-arterial administration of a replication-

selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial." *Gene Ther* **8**(21): 1618-26.

Ren, X. W., Liang, M., Meng, X., Ye, X., Ma, H., Zhao, Y., Guo, J., Cai, N., Chen, H. Z., Ye, S. L. and Hu, F. (2006). "A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma." *Cancer Gene Ther* **13**(2): 159-68.

Reynolds, P. N., Feng, M. and Curiel, D. T. (1999). "Chimeric viral vectors--the best of both worlds?" *Mol Med Today* **5**(1): 25-31.

Reynolds, P. N., Nicklin, S. A., Kaliberova, L., Boatman, B. G., Grizzle, W. E., Balyasnikova, I. V., Baker, A. H., Danilov, S. M. and Curiel, D. T. (2001). "Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo." *Nat Biotechnol* **19**(9): 838-42.

Ridge, J. P., Di Rosa, F. and Matzinger, P. (1998). "A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell." *Nature* **393**(6684): 474-8.

Riedl, S. J. and Shi, Y. (2004). "Molecular mechanisms of caspase regulation during apoptosis." *Nat Rev Mol Cell Biol* **5**(11): 897-907.

Ries, S. J. and Brandts, C. H. (2004). "Oncolytic viruses for the treatment of cancer: current strategies and clinical trials." *Drug Discov Today* **9**(17): 759-68.

Rima, B. K. and Duprex, W. P. (2006). "Morbilliviruses and human disease." *J Pathol* **208**(2): 199-214.

Rizzo, P., Bocchetta, M., Powers, A., Foddìs, R., Stekala, E., Pass, H. I. and Carbone, M. (2001). "SV40 and the pathogenesis of mesothelioma." *Semin Cancer Biol* **11**(1): 63-71.

- Robbins, P. D. and Ghivizzani, S. C. (1998).** "Viral vectors for gene therapy." *Pharmacol Ther* **80**(1): 35-47.
- Robinson, B. W. (1989).** "Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2." *Am Rev Respir Dis* **139**(4): 897-901.
- Robinson, B. W., Mukherjee, S. A., Davidson, A., Morey, S., Musk, A. W., Ramshaw, I., Smith, D., Lake, R., Haenel, T., Garlepp, M., Marley, J., Leong, C., Caminschi, I. and Scott, B. (1998).** "Cytokine gene therapy or infusion as treatment for solid human cancer." *J Immunother* **21**(3): 211-7.
- Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E. and Hellstrom, I. (2003).** "Mesothelin-family proteins and diagnosis of mesothelioma." *Lancet* **362**(9396): 1612-6.
- Robinson, B. W., Musk, A. W. and Lake, R. A. (2005).** "Malignant mesothelioma." *Lancet* **366**(9483): 397-408.
- Robinson, B. W. S. and Lake, R. A. (2005).** "Advances in malignant mesothelioma." *N Engl J Med* **353**(15): 1591-603.
- Robledo, R. and Mossman, B. (1999).** "Cellular and molecular mechanisms of asbestos-induced fibrosis." *J Cell Physiol* **180**(2): 158-66.
- Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W. and Henderson, D. R. (1997).** "Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells." *Cancer Res* **57**(13): 2559-63.
- Roelvink, P. W., Lizonova, A., Lee, J. G., Li, Y., Bergelson, J. M., Finberg, R. W., Brough, D. E., Kovesdi, I. and Wickham, T. J. (1998).** "The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for

adenovirus serotypes from subgroups A, C, D, E, and F." *J Virol* **72**(10): 7909-15.

Roelvink, P. W., Mi Lee, G., Einfeld, D. A., Kovesdi, I. and Wickham, T. J. (1999).

"Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae." *Science* **286**(5444): 1568-71.

Rogers, B. E., Douglas, J. T., Ahlem, C., Buchsbaum, D. J., Frincke, J. and Curiel,

D. T. (1997). "Use of a novel cross-linking method to modify adenovirus tropism." *Gene Ther* **4**(12): 1387-92.

Rogli, V., Sanfilippo, F. and Shelburne, J. (1992). Mesothelioma, in *Pathology of*

Asbestos and Associated Diseases, Little Brown Co., Boston: 109-64.

Romanczuk, H., Galer, C. E., Zabner, J., Barsomian, G., Wadsworth, S. C. and

O'Riordan, C. R. (1999). "Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice." *Hum Gene Ther* **10**(16): 2615-26.

Rosenberg, S. A. (2001). "Progress in human tumour immunology and

immunotherapy." *Nature* **411**(6835): 380-4.

Rots, M. G., Elferink, M. G., Gommans, W. M., Oosterhuis, D., Schalk, J. A.,

Curiel, D. T., Olinga, P., Haisma, H. J. and Groothuis, G. M. (2006). "An ex vivo human model system to evaluate specificity of replicating and non-replicating gene therapy agents." *J Gene Med* **8**(1): 35-41.

Roushdy-Hammady, I., Siegel, J., Emri, S., Testa, J. R. and Carbone, M. (2001).

"Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey." *Lancet* **357**(9254): 444-5.

Rudin, C. M., Cohen, E. E., Papadimitrakopoulou, V. A., Silverman, S., Jr.,

Recant, W., El-Naggar, A. K., Stenson, K., Lippman, S. M., Hong, W. K.

- and Vokes, E. E. (2003).** "An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia." *J Clin Oncol* **21**(24): 4546-52.
- Russell, S. J. (2002).** "RNA viruses as virotherapy agents." *Cancer Gene Ther* **9**(12): 961-6.
- Ryan, C. W., Herndon, J. and Vogelzang, N. J. (1998).** "A review of chemotherapy trials for malignant mesothelioma." *Chest* **113**(1 Suppl): 66S-73S.
- Ryon, J. J., Moss, W. J., Monze, M. and Griffin, D. E. (2002).** "Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles." *Clin Diagn Lab Immunol* **9**(5): 994-1003.
- Saad, R. S., Cho, P., Liu, Y. L. and Silverman, J. F. (2005).** "The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study." *Diagn Cytopathol* **32**(3): 156-9.
- Saeki, Y., Ichikawa, T., Saeki, A., Chiocca, E. A., Tobler, K., Ackermann, M., Breakefield, X. O. and Fraefel, C. (1998).** "Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in *Escherichia coli*: rescue of replication-competent virus progeny and packaging of amplicon vectors." *Hum Gene Ther* **9**(18): 2787-94.
- Sakaguchi, M., Yoshikawa, Y., Yamanouchi, K., Sata, T., Nagashima, K. and Takeda, K. (1986).** "Growth of measles virus in epithelial and lymphoid tissues of cynomolgus monkeys." *Microbiol Immunol* **30**(10): 1067-73.
- Sanlioglu, A. D., Aydin, C., Bozcuk, H., Terzioglu, E. and Sanlioglu, S. (2004).** "Fundamental principals of tumor necrosis factor-alpha gene therapy approach

and implications for patients with lung carcinoma." *Lung Cancer* **44**(2): 199-211.

Saracci, R. and Simonato, L. (2001). "Familial malignant mesothelioma." *Lancet* **358**(9295): 1813-4.

Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., Pipiya, T., Rom, W. N. and Hay, J. G. (2003). "Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points." *Hum Gene Ther* **14**(5): 425-33.

Savontaus, M. J., Sauter, B. V., Huang, T. G. and Woo, S. L. (2002). "Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells." *Gene Ther* **9**(14): 972-9.

Scappaticci, F. A., Smith, R., Pathak, A., Schloss, D., Lum, B., Cao, Y., Johnson, F., Engleman, E. G. and Nolan, G. P. (2001). "Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice." *Mol Ther* **3**(2): 186-96.

Schagen, F. H., Ossevoort, M., Toes, R. E. and Hoeben, R. C. (2004). "Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion." *Crit Rev Oncol Hematol* **50**(1): 51-70.

Schipper, H., Papp, T., Johnen, G., Pemsel, H., Bastrop, R., Muller, K. M., Wiethge, T., Jaworska, M., Krismann, M., Schiffmann, D. and Rahman, Q. (2003). "Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas." *Int J Oncol* **22**(5): 1009-17.

- Schmitz, V., Wang, L., Barajas, M., Gomar, C., Prieto, J. and Qian, C. (2004).**
"Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer of endostatin and angiostatin-like molecule in mice." *Gut* **53**(4): 561-7.
- Schneider, U., Bullough, F., Vongpunsawad, S., Russell, S. J. and Cattaneo, R. (2000).** "Recombinant measles viruses efficiently entering cells through targeted receptors." *J Virol* **74**(21): 9928-36.
- Schneider-Schaulies, S., Bieback, K., Avota, E., Klagge, I. and ter Meulen, V. (2002).** "Regulation of gene expression in lymphocytes and antigen-presenting cells by measles virus: consequences for immunomodulation." *J Mol Med* **80**(2): 73-85.
- Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. (1998).** "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions." *Nature* **393**(6684): 480-3.
- Sebastien, P., Janson, X., Gaudichet, A., Hirsch, A. and Bignon, J. (1980).**
"Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura." *IARC Sci Publ*(30): 237-46.
- Segal, A., Whitaker, D., Henderson, D. and Shilkin, K. (2002).** Pathology of Mesothelioma. Mesothelioma. Robinson, Bws and Chahinian, Ap. London, Martin Dunitz: 143-84.
- Servet-Delprat, C., Vidalain, P. O., Azocar, O., Le Deist, F., Fischer, A. and Roubardin-Combe, C. (2000).** "Consequences of Fas-mediated human dendritic cell apoptosis induced by measles virus." *J Virol* **74**(9): 4387-93.
- Seth, P. (2000).** "Pre-clinical studies with tumor suppressor genes." *Adv Exp Med Biol* **465**: 183-92.

- Seth, P. (2005).** "Vector-mediated cancer gene therapy: an overview." *Cancer Biol Ther* 4(5): 512-7.
- Shaffer, J. A., Bellini, W. J. and Rota, P. A. (2003).** "The C protein of measles virus inhibits the type I interferon response." *Virology* 315(2): 389-97.
- Shenk, T. E. (2001).** *Adenoviridae: the viruses and their replication. Fields' Virology.* Knie, Dm and Howley, Pm. Philadelphia, Lippincott William & Wilkins. 2: 2265-300.
- Shi, W., Teschendorf, C., Muzyczka, N. and Siemann, D. W. (2002).** "Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo." *Cancer Gene Ther* 9(6): 513-21.
- Shivapurkar, N., Harada, K., Reddy, J., Scheuermann, R. H., Xu, Y., McKenna, R. W., Milchgrub, S., Kroft, S. H., Feng, Z. and Gazdar, A. F. (2002).** "Presence of simian virus 40 DNA sequences in human lymphomas." *Lancet* 359(9309): 851-2.
- Singhal, S., Wiewrodt, R., Malden, L. D., Amin, K. M., Matzie, K., Friedberg, J., Kucharczuk, J. C., Litzky, L. A., Johnson, S. W., Kaiser, L. R. and Albelda, S. M. (2003).** "Gene expression profiling of malignant mesothelioma." *Clin Cancer Res* 9(8): 3080-97.
- Sirena, D., Lilienfeld, B., Eisenhut, M., Kalin, S., Boucke, K., Beerli, R. R., Vogt, L., Ruedl, C., Bachmann, M. F., Greber, U. F. and Hemmi, S. (2004).** "The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3." *J Virol* 78(9): 4454-62.
- Sluis-Cremer, G. K. (1991).** "Asbestos disease at low exposures after long residence times." *Ann N Y Acad Sci* 643: 182-93.

- Smith, T. A., White, B. D., Gardner, J. M., Kaleko, M. and McClelland, A. (1996).** "Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector." *Gene Ther* **3**(6): 496-502.
- Spitz, F. R., Nguyen, D., Skibber, J. M., Meyn, R. E., Cristiano, R. J. and Roth, J. A. (1996).** "Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation." *Clin Cancer Res* **2**(10): 1665-71.
- Spugnini, E. P., Bosari, S., Citro, G., Lorenzon, I., Cognetti, F. and Baldi, A. (2006).** "Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression." *Int J Biochem Cell Biol* **38**(12): 2000-4.
- St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B. and Kinzler, K. W. (2000).** "Genes expressed in human tumor endothelium." *Science* **289**(5482): 1197-202.
- St George, J. A. (2003).** "Gene therapy progress and prospects: adenoviral vectors." *Gene Ther* **10**(14): 1135-41.
- Stamenkovic, I. (2000).** "Matrix metalloproteinases in tumor invasion and metastasis." *Semin Cancer Biol* **10**(6): 415-33.
- Stamenkovic, I. (2003).** "Extracellular matrix remodelling: the role of matrix metalloproteinases." *J Pathol* **200**(4): 448-64.
- Stavropoulos, T. A. and Strathdee, C. A. (1998).** "An enhanced packaging system for helper-dependent herpes simplex virus vectors." *J Virol* **72**(9): 7137-43.
- Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M. and Kaiser, L. R. (1998).** "Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of

a phase I clinical trial in malignant mesothelioma." *Hum Gene Ther* **9**(7): 1083-92.

Sterman, D. H., Kaiser, L. R. and Albelda, S. M. (1999). "Advances in the treatment of malignant pleural mesothelioma." *Chest* **116**(2): 504-20.

Sterman, D. H., Molnar-Kimber, K., Iyengar, T., Chang, M., Lanuti, M., Amin, K. M., Pierce, B. K., Kang, E., Treat, J., Recio, A., Litzky, L., Wilson, J. M., Kaiser, L. R. and Albelda, S. M. (2000). "A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma." *Cancer Gene Ther* **7**(12): 1511-8.

Sterman, D. H. (2005). "Gene therapy for malignant pleural mesothelioma." *Hematol Oncol Clin North Am* **19**(6): 1147-73, viii.

Sterman, D. H., Recio, A., Vachani, A., Sun, J., Cheung, L., DeLong, P., Amin, K. M., Litzky, L. A., Wilson, J. M., Kaiser, L. R. and Albelda, S. M. (2005). "Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy." *Clin Cancer Res* **11**(20): 7444-53.

Sterman, D. H., Recio, A., Carroll, R. G., Gillespie, C. T., Haas, A., Vachani, A., Kapoor, V., Sun, J., Hodinka, R., Brown, J. L., Corbley, M. J., Parr, M., Ho, M., Pastan, I., Machuzak, M., Benedict, W., Zhang, X. Q., Lord, E. M., Litzky, L. A., Heitjan, D. F., June, C. H., Kaiser, L. R., Vonderheide, R. H., Albelda, S. M. and Kanther, M. (2007). "A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses." *Clin Cancer Res* **13**(15 Pt 1): 4456-66.

- Sternlicht, M. D. and Werb, Z. (2001).** "How matrix metalloproteinases regulate cell behavior." *Annu Rev Cell Dev Biol* **17**: 463-516.
- Stevenson, S. C., Rollence, M., White, B., Weaver, L. and McClelland, A. (1995).** "Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain." *J Virol* **69**(5): 2850-7.
- Stewart, D. J., Martin-Ucar, A., Pilling, J. E., Edwards, J. G., O'Byrne, K. J. and Waller, D. A. (2004).** "The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma." *Ann Thorac Surg* **78**(1): 245-52.
- Stewart, P. L., Chiu, C. Y., Huang, S., Muir, T., Zhao, Y., Chait, B., Mathias, P. and Nemerow, G. R. (1997).** "Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization." *Embo J* **16**(6): 1189-98.
- Storniolo, A. M., Allerheiligen, S. R. and Pearce, H. L. (1997).** "Preclinical, pharmacologic, and phase I studies of gemcitabine." *Semin Oncol* **24**(2 Suppl 7): S7-2-S7-.
- Strizzi, L., Catalano, A., Vianale, G., Orecchia, S., Casalini, A., Tassi, G., Puntoni, R., Mutti, L. and Procopio, A. (2001).** "Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma." *J Pathol* **193**(4): 468-75.
- Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P. and Lee, P. W. (1998).** "The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus." *Embo J* **17**(12): 3351-62.
- Sugarbaker, D. J., Richards, W. G. and Garcia, J. P. (1997).** "Extrapleural pneumonectomy for malignant mesothelioma." *Adv Surg* **31**: 253-71.

- Sugarbaker, D. J., Flores, R. M., Jaklitsch, M. T., Richards, W. G., Strauss, G. M., Corson, J. M., DeCamp, M. M., Jr., Swanson, S. J., Bueno, R., Lukanich, J. M., Baldini, E. H. and Mentzer, S. J. (1999).** "Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients." *J Thorac Cardiovasc Surg* **117**(1): 54-63; discussion -5.
- Sugarbaker, D. J., Jaklitsch, M. T., Bueno, R., Richards, W., Lukanich, J., Mentzer, S. J., Colson, Y., Linden, P., Chang, M., Capalbo, L., Oldread, E., Neragi-Miandoab, S., Swanson, S. J. and Zellos, L. S. (2004).** "Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies." *J Thorac Cardiovasc Surg* **128**(1): 138-46.
- Summerford, C. and Samulski, R. J. (1998).** "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions." *J Virol* **72**(2): 1438-45.
- Suryanarayana, K., Baczko, K., ter Meulen, V. and Wagner, R. R. (1994).** "Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue." *J Virol* **68**(3): 1532-43.
- Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T. and Alemany, R. (2001).** "A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency." *Clin Cancer Res* **7**(1): 120-6.
- Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M.,**

- Putnam, J. B., Jr., Richli, W. R., Savin, M., Schrump, D. S., Shin, D. M., Shulkin, A., Walsh, G. L., Wait, J., Weill, D. and Waugh, M. K. (1999).** "Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer." *J Natl Cancer Inst* **91**(9): 763-71.
- Swisher, S. G. and Roth, J. A. (2002).** "p53 Gene therapy for lung cancer." *Curr Oncol Rep* **4**(4): 334-40.
- Takayama, K., Reynolds, P. N., Adachi, Y., Kaliberova, L., Uchino, J., Nakanishi, Y. and Curiel, D. T. (2007).** "Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application." *Cancer Gene Ther* **14**(1): 105-16.
- Takeuchi, K., Kadota, S. I., Takeda, M., Miyajima, N. and Nagata, K. (2003).** "Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation." *FEBS Lett* **545**(2-3): 177-82.
- Tang, D. C. and Carbone, D. P. (1993).** "Potential application of gene therapy to lung cancer." *Semin Oncol* **20**(4): 368-73.
- Tangye, S. G., Phillips, J. H. and Lanier, L. L. (2000).** "The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells." *Semin Immunol* **12**(2): 149-57.
- Tatsuo, H., Okuma, K., Tanaka, K., Ono, N., Minagawa, H., Takade, A., Matsuura, Y. and Yanagi, Y. (2000).** "Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins." *J Virol* **74**(9): 4139-45.

- Tatsuo, H., Ono, N., Tanaka, K. and Yanagi, Y. (2000).** "SLAM (CDw150) is a cellular receptor for measles virus." *Nature* **406**(6798): 893-7.
- Tatsuo, H., Ono, N. and Yanagi, Y. (2001).** "Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors." *J Virol* **75**(13): 5842-50.
- Testa, J. R., Pass, H. I. and Carbone, M. (2001).** *Molecular Biology of Mesothelioma. Principles and Practice of Oncology.* De Vita, V, Hellman, S, Rosenberg, S and Wilkins, W. Philadelphia, PA, Lippincott: 1937-43.
- Tomko, R. P., Xu, R. and Philipson, L. (1997).** "HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses." *Proc Natl Acad Sci U S A* **94**(7): 3352-6.
- Tsiouris, A. and Walesby, R. K. (2007).** "Malignant pleural mesothelioma: current concepts in treatment." *Nat Clin Pract Oncol* **4**(6): 344-52.
- Tuting, T., Storkus, W. J. and Lotze, M. T. (1997).** "Gene-based strategies for the immunotherapy of cancer." *J Mol Med* **75**(7): 478-91.
- van Haarst, J. M., Baas, P., Manegold, C., Schouwink, J. H., Burgers, J. A., de Bruin, H. G., Mooi, W. J., van Klaveren, R. J., de Jonge, M. J. and van Meerbeeck, J. P. (2002).** "Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma." *Br J Cancer* **86**(3): 342-5.
- van Meerbeeck, J. P., Baas, P., Debruyne, C., Groen, H. J., Manegold, C., Ardizzoni, A., Gridelli, C., van Marck, E. A., Lentz, M. and Giaccone, G. (1999).** "A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group." *Cancer* **85**(12): 2577-82.
- Vasey, P. A., Shulman, L. N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn, D. H., O'Neill, V., Siddiqui, N., Seiden, M. V. and Kaye, S. B. (2002).** "Phase

I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer." *J Clin Oncol* **20**(6): 1562-9.

Veillette, A. and Latour, S. (2003). "The SLAM family of immune-cell receptors." *Curr Opin Immunol* **15**(3): 277-85.

Verma, I. M. and Somia, N. (1997). "Gene therapy -- promises, problems and prospects." *Nature* **389**(6648): 239-42.

Versnel, M. A., Claesson-Welsh, L., Hammacher, A., Bouts, M. J., van der Kwast, T. H., Eriksson, A., Willemsen, R., Weima, S. M., Hoogsteden, H. C., Hagemeyer, A. and et al. (1991). "Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors." *Oncogene* **6**(11): 2005-11.

Vigne, E., Mahfouz, I., Dedieu, J. F., Brie, A., Perricaudet, M. and Yeh, P. (1999). "RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection." *J Virol* **73**(6): 5156-61.

Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C. and Paoletti, P. (2003). "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma." *J Clin Oncol* **21**(14): 2636-44.

Vollmer, C. M., Ribas, A., Butterfield, L. H., Dissette, V. B., Andrews, K. J., Eilber, F. C., Montejo, L. D., Chen, A. Y., Hu, B., Glaspy, J. A., McBride, W. H. and Economou, J. S. (1999). "p53 selective and nonselective replication

of an E1B-deleted adenovirus in hepatocellular carcinoma." *Cancer Res* **59**(17): 4369-74.

Vorburger, S. A. and Hunt, K. K. (2002). "Adenoviral gene therapy." *Oncologist* **7**(1): 46-59.

Waddington, S. N., McVey, J. H., Bhella, D., Parker, A. L., Barker, K., Atoda, H., Pink, R., Buckley, S. M., Greig, J. A., Denby, L., Custers, J., Morita, T., Francischetti, I. M., Monteiro, R. Q., Barouch, D. H., van Rooijen, N., Napoli, C., Havenga, M. J., Nicklin, S. A. and Baker, A. H. (2008). "Adenovirus serotype 5 hexon mediates liver gene transfer." *Cell* **132**(3): 397-409.

Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., Guggino, W. B., Flotte, T. R., Wine, J. J., Carter, B. J., Reynolds, T. C., Moss, R. B. and Gardner, P. (2002). "A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies." *Hum Gene Ther* **13**(11): 1349-59.

Wagner, J. C., Sleggs, C. A. and Marchand, P. (1960). "Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province." *Br J Ind Med* **17**: 260-71.

Waller, D. A. (2004). "Malignant mesothelioma--British surgical strategies." *Lung Cancer* **45 Suppl 1**: S81-4.

Walther, W. and Stein, U. (2000). "Viral vectors for gene transfer: a review of their use in the treatment of human diseases." *Drugs* **60**(2): 249-71.

- Wang, J. P., Kurt-Jones, E. A. and Finberg, R. W. (2007).** "Innate immunity to respiratory viruses." *Cell Microbiol* **9**(7): 1641-6.
- Wang, X. and Bergelson, J. M. (1999).** "Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection." *J Virol* **73**(3): 2559-62.
- Weder, W., Kestenholz, P., Taverna, C., Bodis, S., Lardinois, D., Jerman, M. and Stahel, R. A. (2004).** "Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma." *J Clin Oncol* **22**(17): 3451-7.
- Weir, B., Zhao, X. and Meyerson, M. (2004).** "Somatic alterations in the human cancer genome." *Cancer Cell* **6**(5): 433-8.
- Wells, D. J. (2004).** "Gene therapy progress and prospects: electroporation and other physical methods." *Gene Ther* **11**(18): 1363-9.
- West, S. D. and Lee, Y. C. (2006).** "Management of malignant pleural mesothelioma." *Clin Chest Med* **27**(2): 335-54.
- Whitaker, D., Henderson, D. W. and Shilkin, K. B. (1992).** "The concept of mesothelioma in situ: implications for diagnosis and histogenesis." *Semin Diagn Pathol* **9**(2): 151-61.
- White, S. C., Anderson, H., Jayson, G. C., Ashcroft, L., Ranson, M. and Thatcher, N. (2000).** "Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma." *Ann Oncol* **11**(2): 201-6.
- Wickham, T. J., Mathias, P., Cheresch, D. A. and Nemerow, G. R. (1993).** "Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment." *Cell* **73**(2): 309-19.

- Wickham, T. J., Segal, D. M., Roelvink, P. W., Carrion, M. E., Lizonova, A., Lee, G. M. and Kovesdi, I. (1996).** "Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies." *J Virol* **70**(10): 6831-8.
- Wickham, T. J., Tzeng, E., Shears, L. L., 2nd, Roelvink, P. W., Li, Y., Lee, G. M., Brough, D. E., Lizonova, A. and Kovesdi, I. (1997).** "Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins." *J Virol* **71**(11): 8221-9.
- Wild, T. F. and Buckland, R. (1995).** "Functional aspects of envelope-associated measles virus proteins." *Curr Top Microbiol Immunol* **191**: 51-64.
- Wirth, T., Zender, L., Schulte, B., Mundt, B., Plentz, R., Rudolph, K. L., Manns, M., Kubicka, S. and Kuhnel, F. (2003).** "A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer." *Cancer Res* **63**(12): 3181-8.
- Wolanski, K. D., Whitaker, D., Shilkin, K. B. and Henderson, D. W. (1998).** "The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses." *Cancer* **82**(3): 583-90.
- Wolf, J. K., Bodurka, D. C., Gano, J. B., Deavers, M., Ramondetta, L., Ramirez, P. T., Levenback, C. and Gershenson, D. M. (2004).** "A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer." *Gynecol Oncol* **94**(2): 442-8.
- Wong, L., Zhou, J., Anderson, D. and Kratzke, R. A. (2002).** "Inactivation of p16INK4a expression in malignant mesothelioma by methylation." *Lung Cancer* **38**(2): 131-6.

- Wright, J. F., Qu, G., Tang, C. and Sommer, J. M. (2003).** "Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector." *Curr Opin Drug Discov Devel* **6**(2): 174-8.
- Xu, R., Sun, X., Tse, L. Y., Li, H., Chan, P. C., Xu, S., Xiao, W., Kung, H. F., Krissansen, G. W. and Fan, S. T. (2003).** "Long-term expression of angiostatin suppresses metastatic liver cancer in mice." *Hepatology* **37**(6): 1451-60.
- Yanagi, Y., Takeda, M. and Ohno, S. (2006).** "Measles virus: cellular receptors, tropism and pathogenesis." *J Gen Virol* **87**(Pt 10): 2767-79.
- Yang, C. T., You, L., Yeh, C. C., Chang, J. W., Zhang, F., McCormick, F. and Jablons, D. M. (2000).** "Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells." *J Natl Cancer Inst* **92**(8): 636-41.
- Yasumoto, K., Mivazaki, K., Nagashima, A., Ishida, T., Kuda, T., Yano, T., Sugimachi, K. and Nomoto, K. (1987).** "Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer." *Cancer Res* **47**(8): 2184-7.
- Yazawa, K., Fisher, W. E. and Brunicardi, F. C. (2002).** "Current progress in suicide gene therapy for cancer." *World J Surg* **26**(7): 783-9.
- Yokota, S., Saito, H., Kubota, T., Yokosawa, N., Amano, K. and Fujii, N. (2003).** "Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex." *Virology* **306**(1): 135-46.
- Young, L. S., Searle, P. F., Onion, D. and Mautner, V. (2006).** "Viral gene therapy strategies: from basic science to clinical application." *J Pathol* **208**(2): 299-318.
- Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E. and Welsh, M. J. (1993).** "Adenovirus-mediated gene transfer transiently corrects the

chloride transport defect in nasal epithelia of patients with cystic fibrosis." *Cell* **75**(2): 207-16.

Zaiss, A. K., Liu, Q., Bowen, G. P., Wong, N. C., Bartlett, J. S. and Muruve, D. A. (2002). "Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors." *J Virol* **76**(9): 4580-90.

Zanella, C. L., Posada, J., Tritton, T. R. and Mossman, B. T. (1996). "Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor." *Cancer Res* **56**(23): 5334-8.

Zeh, H. J., Hurd, S., Storkus, W. J. and Lotze, M. T. (1993). "Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer." *J Immunother Emphasis Tumor Immunol* **14**(2): 155-61.

Zeh, H. J. and Bartlett, D. L. (2002). "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers." *Cancer Gene Ther* **9**(12): 1001-12.

Zellos, L. S. and Sugarbaker, D. J. (2002). "Diffuse malignant mesothelioma of the pleural space and its management." *Oncology (Huntingt)* **16**(7): 907-13; discussion 16-7, 19-20, 25.

Zellos, L. S. and Sugarbaker, D. J. (2002). "Multimodality treatment of diffuse malignant pleural mesothelioma." *Semin Oncol* **29**(1): 41-50.

Zhang, Y., Chirmule, N., Gao, G. P., Qian, R., Croyle, M., Joshi, B., Tazelaar, J. and Wilson, J. M. (2001). "Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages." *Mol Ther* **3**(5 Pt 1): 697-707.

- Zhou, H. S., Liu, D. P. and Liang, C. C. (2004).** "Challenges and strategies: the immune responses in gene therapy." *Med Res Rev* **24**(6): 748-61.
- Zhu, J., Huang, X. and Yang, Y. (2007).** "Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways." *J Virol* **81**(7): 3170-80.
- Zhu, Z. B., Makhija, S. K., Lu, B., Wang, M., Wang, S., Takayama, K., Siegal, G. P., Reynolds, P. N. and Curiel, D. T. (2006).** "Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses." *J Thorac Oncol* **1**(7): 701-11.